Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-alpha 2b: relation to response and HBV genotype

Date
2012
Author
Mach, Tomasz
Boucher, Charles A. B.
Hansen, Bettina E.
Zeuzem, Stefan
Janssen, Harry L. A.
Cakaloglu, Yilmaz
Tabak, Fehmi
Sonneveld, Milan J.
Rijckborst, Vincent
Simon, Krzysztof
Heathcote, E. Jenny
Metadata
Show full item record
Abstract
Background: On-treatment decline of serum hepatitis B surface antigen (HBsAg) may reflect the immunomodulatory effect of pegylated interferon (PEG-IFN) for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB). We compared HBsAg decline across HBV genotypes between combined responders (HBeAg loss and HBV DNA 10,000 copies/ml) and non-responders.
URI
http://hdl.handle.net/20.500.12627/22267
https://doi.org/10.3851/imp1887
Collections